As of September 30, 2019, ABATTIS BIOCEUTICALS CORP carries a market capitalization of 8.65M, placing it among publicly traded companies globally. Its enterprise value stands at 7.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.65M |
| Enterprise Value | 7.71M |
As of September 30, 2019, ABATTIS BIOCEUTICALS CORP has 477.80M shares outstanding.
| Shares Outstanding | 477.80M |
These figures are as of September 30, 2019. The price-to-sales ratio is 31.59, and the price-to-book ratio stands at 1.03.
| PS Ratio | 31.59 |
| PB Ratio | 1.03 |
| P/TBV Ratio | -3.03 |
| P/FCF Ratio | 2.59 |
| P/OCF Ratio | 1.20 |
These figures are as of September 30, 2019. The EV/Sales ratio of 28.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.71M versus a market cap of 8.65M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 28.60 |
As of September 30, 2019, ABATTIS BIOCEUTICALS CORP maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.71, indicating elevated leverage, while an interest coverage ratio of -74.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.73 |
| Quick Ratio | 0.52 |
| Debt / Equity | 14.71 |
| Debt / EBITDA | -0.44 |
| Interest Coverage | -74.10 |
Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP posted a negative return on equity (ROE) of -26.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.84, reflecting losses generated across the asset base. The company generates approximately 269,588.60 in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -26.96 |
| Return on Assets (ROA) | -19.84 |
| Revenue Per Employee | 269,588.60 |
| Employee Count | 1.00 |
Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP recorded 3,873.00 in income tax expense. The company reported a pretax loss of -2.31M and -2.30M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 3,873.00 |
As of the close on November 16, 2026, ABATTIS BIOCEUTICALS CORP's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at -NaN, while the 200-day moving average is 0.00.
| 50-Day Moving Average | -NaN |
Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP generated 269,588.60 in revenue and converted that into -2.30M in net income, yielding earnings per share of 0.00. EBITDA reached -2.71M, while operating income came in at -3.03M.
| Revenue | 269,588.60 |
| Operating Income | -3.03M |
| Pretax Income | -2.31M |
| Net Income | -2.30M |
| EBITDA | -2.71M |
| EBIT | -2.79M |
As of September 30, 2019, ABATTIS BIOCEUTICALS CORP holds 1.81M in cash and equivalents against 1.19M in total debt, resulting in a net debt position of -453,774.80. Total book value stands at 8.37M, with working capital of -989,864.63 providing operational flexibility.
| Cash & Cash Equivalents | 1.81M |
| Total Debt | 1.19M |
| Net Debt | -453,774.80 |
| Equity (Book Value) | 8.37M |
| Book Value Per Share | 0.02 |
| Working Capital | -989,864.63 |
ABATTIS BIOCEUTICALS CORP produced 7.11M in operating cash flow over the twelve months ended September 30, 2019. After subtracting -3.82M in capital expenditures, free cash flow totaled 3.29M - equivalent to 0.01 per share.
| Operating Cash Flow | 7.11M |
| Capital Expenditures | -3.82M |
| Free Cash Flow | 3.29M |
| FCF Per Share | 0.01 |
These figures cover the twelve months ended September 30, 2019. The operating margin of -1,125.03 and net profit margin of -852.40 provide insight into operational efficiency.
| Operating Margin | -1,125.03 |
| Pretax Margin | -857.72 |
| Profit Margin | -852.40 |
| EBITDA Margin | -1,005.27 |
These figures cover the twelve months ended September 30, 2019. Free cash flow yield stands at 38.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.52, meaning ABATTIS BIOCEUTICALS CORP raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.52 |
| FCF Yield | 38.59 |
ABATTIS BIOCEUTICALS CORP's most recent stock split took place on September 11, 2012 with a 5:1 split ratio.
| Last Split Date | 9/11/2012 |
| Split Ratio | 5:1 |
As of September 30, 2019, ABATTIS BIOCEUTICALS CORP has an Altman Z-Score of -34.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -34.77 |
Already premium?